@SteveSage That's a great explanation. My wife is a Phama Rep...

@SteveSage

That's a great explanation. My wife is a Phama Rep and her company uses Medadvisor app to run limited promotions through pharmacies. Regrettably for us (maybe not patients ) the allowed direct patient marketing in Australia is quite limited so while the app is great, useful and convenient and everything else there just don't seem to be enough revenue opportunities to get this thing profitable.

I have been in MDR (at about this price) since 2017. I thought expansion and scalability were the answer but we seem to have discovered a means to still burn $13m a year despite increasing receipts from $8m in FY19 to $38m in FY21.

MDR would make a great public service. Lots of happy customers but no money in it.

There always seems to be something, debtor blow out, new acquisition, new markets but never breakeven or any forecast of a profit and a return for shareholders.

Let's hope FY22 breaks the cycle.